GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioArctic AB (STU:B9A) » Definitions » Float Percentage Of Total Shares Outstanding

BioArctic AB (STU:B9A) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 24, 2024)


View and export this data going back to 2020. Start your Free Trial

What is BioArctic AB Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BioArctic AB's float shares is 0.00 Mil. BioArctic AB's total shares outstanding is 88.32 Mil. BioArctic AB's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BioArctic AB's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BioArctic AB's Institutional Ownership is 16.15%.


BioArctic AB Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

BioArctic AB's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/88.32
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioArctic AB (STU:B9A) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioArctic AB (STU:B9A) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
Address
Warfvinges vag 35, Stockholm, SWE, SE-112 51
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. In addition, the group is also focused on the development of a treatment with a combination of a biodegradable medical device and a drug substance for complete spinal cord injury. Geographically, it derives a majority of its revenue from Asia.

BioArctic AB (STU:B9A) Headlines

No Headlines